Development of Novel Testicular Tissue Organ Culture Systems to Induce in vitro Spermatogenesis

开发新型睾丸组织器官培养系统来诱导体外精子发生

基本信息

  • 批准号:
    10254274
  • 负责人:
  • 金额:
    $ 3.96万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-01 至 2022-05-31
  • 项目状态:
    已结题

项目摘要

Development of Novel Testicular Tissue Organ Culture Systems to Induce in vitro Spermatogenesis Spermatogonial stem cells (SSCs) have a tremendous capacity to regenerate spermatogenesis under proper conditions. Chemotherapy or radiation treatments for cancers or other conditions can destroy the stem cell pool and cause permanent infertility. The only option to preserve the fertility of prepubertal male patients is testicular tissue cryopreservation. When those tissues are thawed, testicular tissue organ culture is an approach to mature those tissues to produce sperm outside of the body. Takehiko Ogawa’s lab produced mouse sperm and offspring from cultures of fresh neonatal testes that were maintained for several months in a pump-driven microfluidic (MF) device. To overcome the bulkiness of the MF device, the same laboratory invented a pumpless microfluidic (PL) device. However, sperm and offspring have not been produced using the PL devices; spermatogenesis was not reported from cryopreserved tissues in the PL system, and the system has not been tested in any other species. This study aims to fill the gaps in knowledge by generating mouse sperm and offspring using the PL devices in cultures of fresh and cryopreserved testes, and to translate this technology to non-human primate and/or human testicular tissues. In addition, to overcome several pitfalls in the PL design, I developed and tested a novel PDMS-roof transwell (PRT) culture system, comprised of a polycarbonate-membrane-transwell and a polydimethylsiloxane (PDMS) roof, to ease device production and simplify sample loading and culture maintenance. The efficiency of in vitro spermatogenesis using the PRT device was similar to the PL device in cultures of fresh neonatal mouse testes (>70% tubules showed Acrosin- GFP+ post-meiotic cells within 1 month in culture). In the PRT system, I confirmed VASA-positive germ cells in 81.6±6.63%, SALL4-positive undifferentiated spermatogonia in 70.1±10.21%, STRA8-positive differentiating spermatogonia in 50.0±14.01%, SYCP3-positive spermatocytes in 75.9±9.2%, and SOX9-positive Sertoli cells in 99.08±0.9% of tubules. A similar experiment using cryopreserved neonatal mouse testes in both culture systems is underway. In a pilot study on immature rhesus macaque testicular tissues using the PRT system, I observed VASA-positive germ cell retention in 90.3% of tubules after 3 months in culture. More detailed analyses are in process. Unlike mouse, monkeys and humans have a prolonged prepubertal period before the initiation of spermatogenesis and there is limited information about the mechanisms that regulate prepubertal to pubertal to adult developmental transitions in testicular somatic cells or germ cells. I will exploit our unique pipeline of healthy rhesus and human testicular tissues from prepubertal, pubertal and adult individuals and perform high-throughput single-cell RNA sequencing to identify a subset of genes with differential expression at these developmental stages. This will provide a novel dataset that will help guide our efforts to develop a simplified, efficient ex vivo testicular tissue organ culture system and translate it toward the human clinic.
开发新型睾丸组织器官培养系统来诱导体外精子发生 精原干细胞(SSC)在适当的条件下具有再生精子发生的巨大能力 状况。针对癌症或其他疾病的化疗或放射治疗可能会破坏干细胞 池并导致永久性不孕。保留青春期前男性患者生育能力的唯一选择是 睾丸组织冷冻保存。当这些组织解冻后,睾丸组织器官培养是一种 使这些组织成熟以在体外产生精子的方法。小川武彦实验室制作 来自新鲜新生儿睾丸培养物的小鼠精子和后代,这些睾丸在培养箱中保存了几个月 泵驱动的微流体(MF)装置。为了克服 MF 设备的笨重,同一实验室 发明了无泵微流体(PL)装置。然而,精子和后代尚未使用 PL设备; PL 系统中的冷冻保存组织未报告精子发生,并且该系统 尚未在任何其他物种中进行过测试。本研究旨在通过生成小鼠来填补知识空白 使用 PL 设备在新鲜和冷冻保存的睾丸培养物中研究精子和后代,并将其转化为 技术应用于非人类灵长类动物和/或人类睾丸组织。此外,为了克服一些陷阱 在 PL 设计中,我开发并测试了一种新型 PDMS-roof transwell (PRT) 培养系统,该系统由 聚碳酸酯膜 Transwell 和聚二甲基硅氧烷 (PDMS) 屋顶,以简化设备生产和 简化样品加载和培养维护。使用 PRT 进行体外精子发生的效率 装置与新鲜新生小鼠睾丸培养物中的 PL 装置相似(>70% 的小管显示顶体素- 培养 1 个月内的 GFP+ 减数分裂后细胞)。在 PRT 系统中,我确认了 VASA 阳性生殖细胞 81.6±6.63%,SALL4阳性未分化精原细胞70.1±10.21%,STRA8阳性分化 精原细胞占 50.0±14.01%,SYCP3 阳性精母细胞占 75.9±9.2%,SOX9 阳性支持细胞 存在于 99.08±0.9% 的肾小管中。使用两种培养物中冷冻保存的新生小鼠睾丸进行的类似实验 系统正在进行中。在使用 PRT 系统对未成熟恒河猴睾丸组织进行的初步研究中,我 培养 3 个月后,观察到 VASA 阳性生殖细胞保留在 90.3% 的肾小管中。更详细 分析正在进行中。与小鼠不同,猴子和人类在进入青春期之前有很长的青春期前时期。 精子发生的启动,关于调节青春期前的机制的信息有限 睾丸体细胞或生殖细胞从青春期到成人的发育转变。我将利用我们独特的 来自青春期前、青春期和成年个体的健康恒河猴和人类睾丸组织的管道,以及 进行高通量单细胞 RNA 测序以鉴定具有差异表达的基因子集 在这些发展阶段。这将提供一个新颖的数据集,有助于指导我们开发 简化、高效的离体睾丸组织器官培养系统,并将其转化为人类临床。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kien T.D. Tran其他文献

Kien T.D. Tran的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Phase I/II clinical trial of autologous T cell gene therapy to treat X-linked lymphoproliferative disease (XLP)
自体T细胞基因疗法治疗X连锁淋巴增殖性疾病(XLP)的I/II期临床试验
  • 批准号:
    MR/Y019458/1
  • 财政年份:
    2024
  • 资助金额:
    $ 3.96万
  • 项目类别:
    Research Grant
Fabrication and Evaluation of Poly(glycerol sebacate) based small diameter vascular graft as a potent substitution for autologous vessels
基于聚(甘油癸二酸酯)的小直径血管移植物作为自体血管有效替代品的制造和评估
  • 批准号:
    2897580
  • 财政年份:
    2023
  • 资助金额:
    $ 3.96万
  • 项目类别:
    Studentship
Autologous Bone Marrow Aspirate Concentrate for the Treatment of Osteonecrosis of the Femoral Head
自体骨髓抽吸浓缩液治疗股骨头坏死
  • 批准号:
    10658324
  • 财政年份:
    2023
  • 资助金额:
    $ 3.96万
  • 项目类别:
Identifying multimodal biomarkers for autologous serum tears in the treatment of chronic postoperative ocular pain
识别治疗慢性术后眼痛的自体血清泪液的多模式生物标志物
  • 批准号:
    10794761
  • 财政年份:
    2023
  • 资助金额:
    $ 3.96万
  • 项目类别:
SBIR Phase II: An Injectable Protein Matrix to Enhance the Stability of Autologous Fat Grafts
SBIR II 期:可注射蛋白质基质,增强自体脂肪移植物的稳定性
  • 批准号:
    2304430
  • 财政年份:
    2023
  • 资助金额:
    $ 3.96万
  • 项目类别:
    Cooperative Agreement
Application of Autologous Connective Tissue Sheets Created in Patients' Bodies to Pediatric Cardiac Valvuloplasty and Development of Dedicated Molds
患者体内自体结缔组织片在小儿心脏瓣膜成形术中的应用及专用模具的开发
  • 批准号:
    23K15543
  • 财政年份:
    2023
  • 资助金额:
    $ 3.96万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
MICA: Strategy for heart repair in Duchenne Muscular Dystrophy (DMD) using genetically engineered autologous Mesoangioblasts
MICA:利用基因工程自体中成血管细胞修复杜氏肌营养不良症 (DMD) 的心脏的策略
  • 批准号:
    MR/X00466X/1
  • 财政年份:
    2023
  • 资助金额:
    $ 3.96万
  • 项目类别:
    Fellowship
Planning a phase I study of minor salivary gland derived autologous MSCs for prevention of long-term radiation induced xerostomia
计划对小唾液腺来源的自体 MSC 进行 I 期研究,以预防长期辐射引起的口干症
  • 批准号:
    10720234
  • 财政年份:
    2023
  • 资助金额:
    $ 3.96万
  • 项目类别:
SBIR PHASE II, TOPIC 429: A NEW PARADIGM FOR AUTOLOGOUS AND ALLOGENEIC CELL THERAPY MANUFACTURING
SBIR 第二阶段,主题 429:自体和同种异体细胞治疗制造的新范式
  • 批准号:
    10976161
  • 财政年份:
    2023
  • 资助金额:
    $ 3.96万
  • 项目类别:
HIV Reservoir and Gene Modified Cell Dynamics Following Autologous Stem Cell Transplantation
自体干细胞移植后的 HIV 储库和基因修饰细胞动力学
  • 批准号:
    10700521
  • 财政年份:
    2023
  • 资助金额:
    $ 3.96万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了